PL1874306T3 - Kompozycje zawierające 1,2,4-oksadiazol aktywny po podaniu doustnie w celu supresyjnego leczenia niesensownej mutacji - Google Patents

Kompozycje zawierające 1,2,4-oksadiazol aktywny po podaniu doustnie w celu supresyjnego leczenia niesensownej mutacji

Info

Publication number: PL1874306T3
Authority: PL; Poland
Prior art keywords: oxadiazole; compositions; nonsense mutation; orally active; suppression therapy
Prior art date: 2005-04-08

Application number

PL06749439T

Other languages

English (en)

Polish (pl)

Inventor

Samit Hirawat

Langdon Miller

Original Assignee

Ptc Therapeutics Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-04-08

Filing date

2006-04-06

Publication date

2012-11-30

2006-04-06 Application filed by Ptc Therapeutics Inc filed Critical Ptc Therapeutics Inc

2012-11-30 Publication of PL1874306T3 publication Critical patent/PL1874306T3/pl

Links

BBVIDBNAYOIXOE-UHFFFAOYSA-N 1,2,4-oxadiazole Chemical compound C=1N=CON=1 BBVIDBNAYOIXOE-UHFFFAOYSA-N 0.000 title 1
108020004485 Nonsense Codon Proteins 0.000 title 1
239000000203 mixture Substances 0.000 title 1
230000037434 nonsense mutation Effects 0.000 title 1
230000001629 suppression Effects 0.000 title 1
238000002560 therapeutic procedure Methods 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/04—Drugs for disorders of the urinary system for urolithiasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Diabetes (AREA)
Neurology (AREA)
Hematology (AREA)
Epidemiology (AREA)
Physical Education & Sports Medicine (AREA)
Endocrinology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Orthopedic Medicine & Surgery (AREA)
Obesity (AREA)
Immunology (AREA)
Urology & Nephrology (AREA)
Rheumatology (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Oncology (AREA)
Pulmonology (AREA)
Nutrition Science (AREA)
Physiology (AREA)
Psychology (AREA)
Pain & Pain Management (AREA)
Psychiatry (AREA)
Hospice & Palliative Care (AREA)
Child & Adolescent Psychology (AREA)
Ophthalmology & Optometry (AREA)

PL06749439T 2005-04-08 2006-04-06 Kompozycje zawierające 1,2,4-oksadiazol aktywny po podaniu doustnie w celu supresyjnego leczenia niesensownej mutacji PL1874306T3 (pl)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US66978905P	2005-04-08	2005-04-08
US78739506P	2006-03-30	2006-03-30
EP06749439A EP1874306B1 (en)	2005-04-08	2006-04-06	Compositions of an orally active 1,2,4-oxadiazole for nonsense mutation suppression therapy
PCT/US2006/012887 WO2006110483A1 (en)	2005-04-08	2006-04-06	Compositions of an orally active 1,2,4-oxadiazole for nonsense mutation suppression therapy

Publications (1)

Publication Number	Publication Date
PL1874306T3 true PL1874306T3 (pl)	2012-11-30

Family

ID=36763092

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
PL06749439T PL1874306T3 (pl)	2005-04-08	2006-04-06	Kompozycje zawierające 1,2,4-oksadiazol aktywny po podaniu doustnie w celu supresyjnego leczenia niesensownej mutacji
PL11175569T PL2402002T3 (pl)	2005-04-08	2006-04-06	Kompozycje zawierające kwas 1,2,4-oksadiazolobenzoesowy i ich zastosowania do leczenia chorób związanych z przedwczesnym kodonem stop

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
PL11175569T PL2402002T3 (pl)	2005-04-08	2006-04-06	Kompozycje zawierające kwas 1,2,4-oksadiazolobenzoesowy i ich zastosowania do leczenia chorób związanych z przedwczesnym kodonem stop

Country Status (16)

Country	Link
US (7)	US8716321B2 (pt)
EP (2)	EP1874306B1 (pt)
JP (3)	JP5800451B2 (pt)
CN (1)	CN103720688A (pt)
AU (1)	AU2006235115C1 (pt)
BR (1)	BRPI0609089A2 (pt)
CA (1)	CA2603402C (pt)
DK (2)	DK2402002T3 (pt)
ES (2)	ES2683359T3 (pt)
IL (2)	IL186433A (pt)
MX (1)	MX2007012206A (pt)
NO (2)	NO339909B1 (pt)
NZ (1)	NZ562197A (pt)
PL (2)	PL1874306T3 (pt)
PT (2)	PT2402002T (pt)
WO (1)	WO2006110483A1 (pt)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
HUE047569T2 (hu)	2003-04-11	2020-04-28	Ptc Therapeutics Inc	1,2,4-oxadiazol-benzoesav vegyület és nonszensz szupresszióra történõ alkalmazása
PT2402002T (pt)	2005-04-08	2018-10-08	Ptc Therapeutics Inc	Composições de 1,2,4-oxadiazole oralmente activo para terapia de supressão de mutações nonsense
RU2462246C2 (ru)	2006-03-30	2012-09-27	ПиТиСи ТЕРАПЬЮТИКС, ИНК.	Способы получения функционального белка из днк, имеющей нонсенс-мутацию, и лечения нарушений, ассоциированных с ней
NZ571803A (en)	2006-04-07	2011-12-22	Vertex Pharma	Amide indole derivatives as modulators of ATP-binding cassette transporters
USRE50453E1 (en)	2006-04-07	2025-06-10	Vertex Pharmaceuticals Incorporated	Indole derivatives as CFTR modulators
US10022352B2 (en)	2006-04-07	2018-07-17	Vertex Pharmaceuticals Incorporated	Modulators of ATP-binding cassette transporters
US7645789B2 (en)	2006-04-07	2010-01-12	Vertex Pharmaceuticals Incorporated	Indole derivatives as CFTR modulators
MX2009002439A (es)	2006-09-08	2009-03-27	Ptc Therapeutics Inc	Procesos para la preparacion de acidos 1,2,4-oxadiazolbenzoicos.
US8101641B2 (en)	2006-09-25	2012-01-24	Ptc Therapeutics, Inc.	Hydroxylated 1,2,4-oxadiazole benzoic acid compounds and compositions thereof
PL2076501T3 (pl) *	2006-09-25	2016-06-30	Ptc Therapeutics Inc	Postacie krystaliczne kwasu 3-[5-(2-fluorofenylo)[1,2,4]oksadiazol-3-ilo]-benzoesowego
AU2016262645B2 (en) *	2006-10-12	2018-05-17	Ptc Therapeutics, Inc.	Methods for dosing an orally active 1,2,4-oxadiazole for nonsense mutation suppression therapy
RS54025B1 (sr) *	2006-10-12	2015-10-30	Ptc Therapeutics Inc.	Postupci doziranja oralno aktivnog 1,2,4-oksadiazola za supresionu terapiju nonsens mutacije
US8563573B2 (en)	2007-11-02	2013-10-22	Vertex Pharmaceuticals Incorporated	Azaindole derivatives as CFTR modulators
GB0715087D0 (en)	2007-08-03	2007-09-12	Summit Corp Plc	Drug combinations for the treatment of duchenne muscular dystrophy
CA2685540C (en)	2007-08-03	2018-10-16	Graham Michael Wynne	Drug combinations for the treatment of duchenne muscular dystrophy
SI2217572T1 (sl)	2007-11-16	2014-05-30	Vertex Pharmaceuticals Incorporated	Izokinolinski modulatorji prenaĺ alcev z atp-vezavno kaseto
SI2225230T1 (sl)	2007-12-07	2017-03-31	Vertex Pharmaceuticals Incorporated	Trdne oblike 3-(6-(1-2,2-difluorobenzo(d)(1,3)dioxol-5-il)ciklopropan- karboksamido)-3-metilpiridin-2-il) benzojske kisline
EP2271621B1 (en)	2008-03-31	2013-11-20	Vertex Pharmaceuticals Incorporated	Pyridyl derivatives as cftr modulators
US20110251253A1 (en)	2010-03-25	2011-10-13	Vertex Pharmaceuticals Incorporated	Solid forms of (r)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-n-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl) cyclopropanecarboxamide
US8802868B2 (en)	2010-03-25	2014-08-12	Vertex Pharmaceuticals Incorporated	Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide
HRP20211752T1 (hr)	2010-04-07	2022-02-18	Vertex Pharmaceuticals Incorporated	Farmaceutski pripravci 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioksol-5-il)ciklopropankarboksamido)-3-metilpiridin-2-il)benzojeve kiseline i njihova primjena
HRP20160682T1 (hr)	2010-04-07	2016-07-29	Vertex Pharmaceuticals Incorporated	Čvrsti oblici 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioksol-5-il)ciklopropankarboksiamido)-3-metilpiridin-2-il)benzojeve kiseline
ES2608474T3 (es)	2010-04-22	2017-04-11	Vertex Pharmaceuticals Incorporated	Proceso de producción de compuestos indol cycloalkylcarboxamido
US8563593B2 (en)	2010-06-08	2013-10-22	Vertex Pharmaceuticals Incorporated	Formulations of (R)-1-(2,2-difluorobenzo[D] [1,3] dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide
JP5877200B2 (ja)	2010-08-05	2016-03-02	ユニヴェルシテドゥドロワエサンテドゥリール	ナンセンス突然変異による疾患の治療に有用な化合物及びその化合物を含む医薬組成物
CA2808501A1 (en)	2010-08-23	2012-03-01	Vertex Pharmaceuticals Incorporated	Pharmaceutical composition of (r)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-n-(1-(2,3-dihydroxy propyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl) cyclopropanecarboxamide and administration therof
IN2014KN00885A (pt)	2011-11-08	2015-10-02	Vertex Pharma
WO2013112804A1 (en)	2012-01-25	2013-08-01	Vertex Pharmaceuticals Incorporated	Formulations of 3-(6-(1-(2.2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
WO2014014841A1 (en)	2012-07-16	2014-01-23	Vertex Pharmaceuticals Incorporated	Pharmaceutical compositions of (r)-1-(2,2-diflurorbenzo[d][1,3]dioxol-5-yl)-n-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl) cyclopropanecarboxamide and administration thereof
LT3470063T (lt)	2012-11-02	2025-02-10	Vertex Pharmaceuticals Incorporated	Farmacinės kompozicijos, skirtos cftr nulemtų ligų gydymui
WO2014153643A1 (en) *	2013-03-26	2014-10-02	The University Of British Columbia	Compositions and methods for use thereof in the treatment of aniridia
KR102497273B1 (ko)	2014-03-06	2023-02-07	피티씨 테라퓨틱스, 인크.	1,2,4-옥사디아졸 벤조산의 약학 조성물 및 염
ES2885181T3 (es)	2014-04-15	2021-12-13	Vertex Pharma	Composiciones farmacéuticas para el tratamiento de enfermedades mediadas por el regulador de la conductancia transmembrana de fibrosis quística
US20170196842A1 (en) *	2014-06-06	2017-07-13	Ptc Therapeutics, Inc.	Methods of treatment using a 1,2,4-oxadiazole benzoic acid
TWI735416B (zh)	2014-10-06	2021-08-11	美商維泰克斯製藥公司	囊腫纖維化症跨膜傳導調節蛋白之調節劑
JP2018531975A (ja)	2015-10-30	2018-11-01	ピーティーシーセラピューティクス，インコーポレーテッド	てんかんの治療方法
US11135221B2 (en)	2015-12-23	2021-10-05	Moonshot Pharma Llc	Methods for inducing an immune response
TW201808922A (zh)	2016-06-20	2018-03-16	台灣神隆股份有限公司	製備阿塔魯仁及其中間體的方法
WO2018050706A1 (en) *	2016-09-13	2018-03-22	Marco Cipolli	Method of treatment of shwachman-diamond syndrome
JP2020525434A (ja)	2017-06-22	2020-08-27	ムーンショットファーマエルエルシー	アンレキサノクス及び免疫調節剤を含む組成物で癌を治療する方法
PE20201170A1 (es)	2017-11-01	2020-10-28	Bristol Myers Squibb Co	Compuestos biciclicos en puente como moduladores del receptor farnesoide x
EP3713934B1 (en)	2017-11-23	2022-04-13	Universita' degli Studi di Palermo	Oxadiazole derivatives for the treatment of genetic diseases due to nonsense mutations
WO2020128816A2 (en)	2018-12-20	2020-06-25	Pfizer Inc.	Pharmaceutical compositions and methods comprising a combination of a benzoxazole transthyretin stabilizer and an additional therapeutic agent
AR118050A1 (es)	2019-02-15	2021-09-15	Bristol Myers Squibb Co	Compuestos bicíclicos sustituidos como moduladores del receptor farnesoide x
KR20210129684A (ko)	2019-02-15	2021-10-28	브리스톨-마이어스 스큅 컴퍼니	파르네소이드 x 수용체 조정제로서 유용한 치환된 아미드 화합물
AU2020221370A1 (en)	2019-02-15	2021-10-07	Bristol-Myers Squibb Company	Substituted bicyclic compounds as farnesoid x receptor modulators
CN113677659B (zh)	2019-02-15	2024-09-06	百时美施贵宝公司	可用作类法尼醇x受体调节剂的经取代的酰胺化合物
EP3952867A4 (en) *	2019-04-10	2023-01-11	PTC Therapeutics, Inc.	METHODS OF TREATMENT OF NONSENSE MUTATION MEDIATED DUCHENNE MUSCULAR DYSTROPHY IN PEDIATRIC PATIENTS
WO2022112919A1 (en)	2020-11-25	2022-06-02	Pfizer Inc.	(aza)benzothiazolyl substituted pyrazole compounds
KR102665711B1 (ko) *	2021-12-21	2024-05-14	재단법인 아산사회복지재단	Ras 활성도를 이용한 신경섬유종증 치료제에 대한 감수성 예측용 바이오마커 조성물 및 Ras 활성 억제제를 포함하는 신경섬유종증 예방 또는 치료용 약학적 조성물
CN114920667B (zh) *	2022-06-30	2024-06-21	湖南大学	一种阿塔鲁伦酯的电化学制备方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
MY128323A (en) *	1996-09-30	2007-01-31	Otsuka Pharma Co Ltd	Thiazole derivatives for inhibition of cytokine production and of cell adhesion
FI107732B (fi) *	1998-03-18	2001-09-28	Xyrofin Oy	Laktitolin kiteyttäminen, kiteinen laktitolituote ja sen käyttö
US6660753B2 (en)	1999-08-19	2003-12-09	Nps Pharmaceuticals, Inc.	Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
US6316029B1 (en)	2000-05-18	2001-11-13	Flak Pharma International, Ltd.	Rapidly disintegrating solid oral dosage form
JP2005504014A (ja)	2001-06-08	2005-02-10	サイトビアインコーポレイテッド	カスパーゼの活性化因子およびアポトーシスの誘導因子としての置換された３−アリール−５−アリール−［１，２，４］−オキサジアゾール類および類似体、並びにその使用法
MY151199A (en)	2001-11-02	2014-04-30	Rigel Pharmaceuticals Inc	Substituted diphenyl heterocycles useful for treating hcv infection
TW200424183A (en)	2002-08-09	2004-11-16	Nps Pharma Inc	New compounds
US20040253307A1 (en) *	2003-02-04	2004-12-16	Brian Hague	Sugar-free oral transmucosal solid dosage forms and uses thereof
GB0303503D0 (en)	2003-02-14	2003-03-19	Novartis Ag	Organic compounds
HUE047569T2 (hu)	2003-04-11	2020-04-28	Ptc Therapeutics Inc	1,2,4-oxadiazol-benzoesav vegyület és nonszensz szupresszióra történõ alkalmazása
WO2004110351A2 (en)	2003-05-14	2004-12-23	Anadys Pharmaceuticals, Inc.	Heterocyclic compounds for treating hepatitis c virus
PT2402002T (pt)	2005-04-08	2018-10-08	Ptc Therapeutics Inc	Composições de 1,2,4-oxadiazole oralmente activo para terapia de supressão de mutações nonsense
US20070010553A1 (en)	2005-07-01	2007-01-11	Astrazeneca Ab	New use
MX2009002439A (es)	2006-09-08	2009-03-27	Ptc Therapeutics Inc	Procesos para la preparacion de acidos 1,2,4-oxadiazolbenzoicos.
PL2076501T3 (pl)	2006-09-25	2016-06-30	Ptc Therapeutics Inc	Postacie krystaliczne kwasu 3-[5-(2-fluorofenylo)[1,2,4]oksadiazol-3-ilo]-benzoesowego
KR102497273B1 (ko)	2014-03-06	2023-02-07	피티씨 테라퓨틱스, 인크.	1,2,4-옥사디아졸 벤조산의 약학 조성물 및 염

2006
- 2006-04-06 PT PT11175569T patent/PT2402002T/pt unknown
- 2006-04-06 ES ES11175569.0T patent/ES2683359T3/es not_active Expired - Lifetime
- 2006-04-06 EP EP06749439A patent/EP1874306B1/en not_active Expired - Lifetime
- 2006-04-06 JP JP2008505534A patent/JP5800451B2/ja not_active Expired - Lifetime
- 2006-04-06 CA CA2603402A patent/CA2603402C/en not_active Expired - Lifetime
- 2006-04-06 CN CN201310655012.3A patent/CN103720688A/zh active Pending
- 2006-04-06 DK DK11175569.0T patent/DK2402002T3/en active
- 2006-04-06 AU AU2006235115A patent/AU2006235115C1/en not_active Expired
- 2006-04-06 PL PL06749439T patent/PL1874306T3/pl unknown
- 2006-04-06 US US11/918,114 patent/US8716321B2/en active Active
- 2006-04-06 ES ES06749439T patent/ES2390804T3/es not_active Expired - Lifetime
- 2006-04-06 BR BRPI0609089-3A patent/BRPI0609089A2/pt not_active Application Discontinuation
- 2006-04-06 PT PT06749439T patent/PT1874306E/pt unknown
- 2006-04-06 MX MX2007012206A patent/MX2007012206A/es active IP Right Grant
- 2006-04-06 WO PCT/US2006/012887 patent/WO2006110483A1/en not_active Ceased
- 2006-04-06 DK DK06749439.3T patent/DK1874306T3/da active
- 2006-04-06 NZ NZ562197A patent/NZ562197A/en unknown
- 2006-04-06 EP EP11175569.0A patent/EP2402002B1/en not_active Expired - Lifetime
- 2006-04-06 PL PL11175569T patent/PL2402002T3/pl unknown
2007
- 2007-10-07 IL IL186433A patent/IL186433A/en active IP Right Grant
- 2007-11-07 NO NO20075682A patent/NO339909B1/no unknown
2013
- 2013-06-04 JP JP2013117678A patent/JP5808367B2/ja not_active Expired - Lifetime
2014
- 2014-03-21 US US14/221,352 patent/US9474743B2/en not_active Expired - Lifetime
- 2014-12-30 IL IL236518A patent/IL236518B/en active IP Right Grant
2015
- 2015-07-06 JP JP2015134950A patent/JP2015212292A/ja active Pending
2016
- 2016-10-12 US US15/291,173 patent/US10034863B2/en not_active Expired - Lifetime
2017
- 2017-01-09 NO NO20170035A patent/NO340617B1/no unknown
2018
- 2018-06-28 US US16/021,419 patent/US10285980B2/en not_active Expired - Lifetime
2019
- 2019-03-29 US US16/368,992 patent/US10675272B2/en not_active Expired - Fee Related
2020
- 2020-05-05 US US16/866,822 patent/US11497736B2/en not_active Expired - Lifetime
2022
- 2022-10-11 US US17/963,838 patent/US20230218587A1/en not_active Abandoned

Also Published As

Publication number	Publication date
EP1874306B1 (en)	2012-07-04
JP5800451B2 (ja)	2015-10-28
US10034863B2 (en)	2018-07-31
PL2402002T3 (pl)	2018-11-30
AU2006235115B2 (en)	2012-07-05
US10285980B2 (en)	2019-05-14
PT1874306E (pt)	2012-10-11
HK1111897A1 (en)	2008-08-22
ES2390804T3 (es)	2012-11-16
BRPI0609089A2 (pt)	2010-11-16
US9474743B2 (en)	2016-10-25
US20190224173A1 (en)	2019-07-25
NO339909B1 (no)	2017-02-13
IL236518B (en)	2018-07-31
US20140221436A1 (en)	2014-08-07
MX2007012206A (es)	2007-12-05
US20230218587A1 (en)	2023-07-13
US11497736B2 (en)	2022-11-15
US20180311219A1 (en)	2018-11-01
US20090149513A1 (en)	2009-06-11
EP2402002B1 (en)	2018-07-11
CN103720688A (zh)	2014-04-16
IL186433A (en)	2015-01-29
IL186433A0 (en)	2008-08-07
AU2006235115A1 (en)	2006-10-19
NO20170035A1 (no)	2008-01-07
US10675272B2 (en)	2020-06-09
CA2603402A1 (en)	2006-10-19
JP2015212292A (ja)	2015-11-26
JP5808367B2 (ja)	2015-11-10
EP2402002A1 (en)	2012-01-04
EP1874306A1 (en)	2008-01-09
US8716321B2 (en)	2014-05-06
IL236518A0 (en)	2015-02-26
WO2006110483A1 (en)	2006-10-19
US20170027913A1 (en)	2017-02-02
JP2008535846A (ja)	2008-09-04
DK1874306T3 (da)	2012-10-01
NO20075682L (no)	2008-01-07
PT2402002T (pt)	2018-10-08
DK2402002T3 (en)	2018-08-20
NO340617B1 (no)	2017-05-15
AU2006235115C1 (en)	2013-02-28
US20200261425A1 (en)	2020-08-20
ES2683359T3 (es)	2018-09-26
CA2603402C (en)	2017-10-31
NZ562197A (en)	2010-09-30
JP2013189465A (ja)	2013-09-26

Publication	Publication Date	Title
IL236518A0 (en)	2015-02-26	Compounds of active 4,2,1-oxadiazole for oral administration for the treatment of suppression of nonsense mutation
IL236519A0 (en)	2015-02-26	Dosing methods of active 4,2,1-oxadiazole in oral administration to suppress non-sense mutation
ME03786B (me)	2021-04-20	Farmaceutske kompozicije amorfnog oblika n-[2,4-bis(1,1-dimetiletil)-5-hidroksifenil]-1,4-dihidro-4-oksohinolin-3-karboksamida
TWI369987B (en)	2012-08-11	New pharmaceutical compositions for the treatment of hyper-proliferative disorders
WO2008027542A3 (en)	2008-04-17	5-substituted isoindoline compounds
WO2007027527A3 (en)	2007-05-24	Isoindole-imide compounds and compositions comprising and methods of using the same
WO2009144555A8 (en)	2010-12-16	Pyrazolospiroketone acetyl-coa carboxylase inhibitors
ZA200802762B (en)	2015-11-25	Pharmaceutical compositions for the treatment of inner ear disorders
PL1981915T3 (pl)	2018-09-28	Kompozycje składników aktywnych
LT2821494T (lt)	2017-04-25	1,4-butandiolio ir jo pirmtakų biosintezės būdai ir kompozicijos
IL186267A0 (en)	2008-01-20	New pharmaceutical compositions for treatment of thrombosis
IL183689A (en)	2010-12-30	Pharmaceutical compositions for improving the structure and function of arterioles
UA92641C2 (ru)	2010-11-25	Комбинированная препаративная форма, которая содержит амлодипин и лозартан
IL222557A (en)	2016-09-29	A compound for use in treating mutant disorders has ruled
MY140514A (en)	2009-12-31	Triazolopyridine derivatives as inhibitors of lipases and phospholipases
AU2007243282A8 (en)	2008-11-27	Compositions and methods for the treatment of cardiovascular disease
ZA200800564B (en)	2008-12-31	Compositions for reducing the incidence of drug induced arrythmia
NO20090193L (no)	2009-01-29	Substituerte heterocykliske etere og anvendelse derav i CNS forstyrrelser
IL199239A0 (en)	2010-03-28	Processes for the preparation of 3-(4-(2,4-difluorobenzyloxy)-3-bromo-6-
WO2008076784A3 (en)	2008-10-23	Methods and compositions for treating il-4 or il-13 related fibrosis related pathologies
AU2006243194A8 (en)	2006-11-09	4-phenyl-5-oxo-l,4,5,6,7,8-hexahydroquinoline derivatives as medicaments for the treatment of infertility
EP2023894A4 (en)	2010-10-20	FIXED COMBINATION DOSAGE FOR TREATING MIGRAINE
PT2474528E (pt)	2014-10-28	Compostos antineoplásicos e composições farmacêuticas dos mesmos
IL189459A (en)	2015-08-31	Use of triazole history to prepare a drug for the treatment and prevention of disease, a number of such history and a pharmaceutical composition containing a number of these
WO2005092334A3 (en)	2006-03-23	Use of n-substituted imino sugars for appetite suppression